

### **Amendments to the claims**

The listing of claims will replace all prior versions, and listings, of claims in the application.

#### **Listing of Claims**

Claims 1-14. Canceled without prejudice.

15. (New) A method of treating or preventing pain which comprises administering to a patient in need of such treatment and prevention a therapeutically or prophylactically effective amount of a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the pain is thoracic outlet obstruction syndrome.

16. (New) A method of treating or preventing pain which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the pain is a compression and entrapment neuropathy.

17. (New) The method of claim 16, wherein the compression and entrapment neuropathy is ulnar nerve palsy, carpal tunnel syndrome, peroneal nerve palsy, or radial nerve palsy.

18. (New) A method of treating or preventing pain which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the pain is Guillain-Barré syndrome.

19. (New) A method of treating or preventing pain which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the pain is associated with or results from: trauma caused by injury or surgical operation; tumors; bony hyperostosis; casts; crutches; prolonged cramped postures; hemorrhage into a nerve;

exposure to cold or radiation; a collagen-vascular disorder; a metabolic disease or disorder; an infectious disease; a toxin; autoimmune reactions; or nutritional deficiency.

20. (New) The method of claim 19, wherein the metabolic disease or disorder is hypothyroidism, porphyria, sarcoidosis, amyloidosis, uremia, or diabetes.

21. (New) The method of claim 19, wherein the infectious disease is Lyme disease or HIV.

22. (New) The method of claim 19, wherein the toxin is emetine, hexobarbital, barbital, chlorobutanol, sulfonamides, phenytoin, nitrofurantoin, the vinca alkaloids, heavy metals, carbon monoxide, triorthocresylphosphate, or orthodinitrophenol.

23. (New) The method of claim 19, wherein the nutritional deficiency is vitamin B deficiency.

24. (New) The method of claim 15, 16, 18 or 19, wherein the sibutramine metabolite is (R/S)-desmethylsibutramine, (R)-desmethylsibutramine, (S)-desmethylsibutramine, (R/S)-didesmethylsibutramine, (R)-didesmethylsibutramine, or (S)-didesmethylsibutramine.

25. (New) The method of claim 24, wherein the sibutramine metabolite is (R)-didesmethylsibutramine.

26. (New) The method of claim 24, wherein the sibutramine metabolite is (S)-didesmethylsibutramine.